Key AASLD 2015 HCV Abstracts: Dr. Lebovics

Posted on October 30, 2015

For more information on the selected AASLD 2015 HCV abstracts below and others to be presented at The International Liver Congress™, please click here to review the Congress abstract e-book.

Decreased work productivity in patients with chronic hepatitis C
Abstract 18
Reduced Work Productivity (WP), Absenteeism and Presenteeism of Patients Infected with Hepatitis C Virus (HCV) are Independently Predicted by Physical Component of Patient-Reported Outcomes (PROs)
Zobair M. Younossi1,2, Maria Stepanova3, Linda Henry3, Issah Younossi3, Ali A. Weinstein3, Fatema Nader1, Sharon L. Hunt3; 1Center For Liver Disease, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA; 2Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA; 3Center for Outcomes Research in Liver Disease, Washington, DC

Hepatocellular carcinoma risk post-SVR
Abstract 90
Incidence and Predictors of hepatocellular Carcinoma following Sustained Virological Response: A national Cohort Study
Hashem B. El-Serag2, Peter Richardson1, Fasiha Kanwal1; 1Medicine/Gastroenterology and Hepatology, Emory University, Houston, TX; 2Houston VA Med Center and Baylor College of Medicine, Houston, TX

1-step diagnostic HCV-Ag EIA
Abstract 85
A Highly Specific and Sensitive Hepatitis C Virus Antigens Enzyme Immunoassay (HCV-Ags EIA) for One-step Diagnosis of HCV Infection
Ke-Qin Hu, Wei Cui; University of California, Irvine, School of Medicine, Orange, CA

EASL non-invasive assessment of fibrosis recommendations
Abstract 117
Evaluation of EASL recommendation for the non-invasive diagnosis of liver fibrosis in chronic hepatitis C
Jerome Boursier1,3, Victor de Ledinghen2, Vincent Leroy4, Oberti Frederic1,3, Isabelle Fouchard-Hubert1,3, Paul Cales1,3; 1Hepato-gastroenterology Department, University Hospital, Angers, France; 2Hepatology Department, University Hospital, Bordeaux, France; 3HIFIH Laboratory EA3859, University, Angers, France; 4Hepato-Gastroenterology Department, University Hospital, Grenoble, France

Cost of therapy
 Abstract 151
The Cost of Making Hepatitis C a Rare Disease in the United States
Jagpreet Chhatwal1, Xiaojie Wang1,2, Mark S. Roberts3, Mina Kabiri3, Turgay Ayer2, Julie M. Donohue3, Fasiha Kanwal4; 1Health Services Research, MD Anderson Cancer Center, Houston, TX; 2Industrial and Systems Engineering, Georgia Institute of Technology, Atlanta, GA; 3Health Policy & Management, University of Pittsburgh, Pittsburgh, PA; 4Houston Veterans Affairs Health Services Research and Development Center of Excellence, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX

Abstract 152
Treating Hepatitis C in the US: measuring impact and value in the context of other major health interventions
Mai T. Pho1, Andrew I. Aronsohn1, Benjamin P. Linas2, Daniel C. Johnson1, Jake R. Morgan2, William V. Padula1, David O. Meltzer1; 1Medicine, University of Chicago, Chicago, IL; 2Boston Medical Center, Boston, MA

Delisting decompensated cirrhotics post-SVR
 Abstract 95
Improving liver function and delisting of patients awaiting liver transplantation for HCV cirrhosis: do we ask too much to DAA?
Audrey Coilly1,2, Georges-Philippe Pageaux22, Pauline Houssel-Debry7, Christophe Duvoux3, Sylvie Radenne6, Victor de Ledinghen15, Danielle Botta-Fridlund11, Anaïs Vallet-Pichard13, Rodolphe Anty9, Vincent Di Martino5, Filomena Conti10, Marie Line Debette-Gratien20, Laurent Alric16, Armando Abergel17, Camille Besch19, Helene Montialoux18, Pascal Lebray10, Sebastien Dharancy4, Francois Durand12, Louis d’Alteroche21, Florian Charier8, Olivier Chazouillères14, Jérôme Dumortier24, Vincent Leroy23, Jean-Charles Duclos-Vallee1,2; 1Centre Hepato-Biliaire, AP-HP Hopital Paul-Brousse, Villejuif, France; 2Unit 1193, INSERM, Villejuif, France; 3AP-HP Hopital Henri Mondor, Creteil, France; 4CHRU de Lille, Lille, France; 5CHU Jean Minjoz, Besançon, France; 6HCL – Hopital Croix Rousse, Lyon, France; 7CHU de Rennes – Hopital Pontchaillou, Renes, France; 8CHU de Poitiers, Poitiers, France; 9CHU de Nice, Nice, France; 10AP-HP Hopital Pitie-Salpetrière, Paris, France; 11AP-HM Hopital La Conception, Marseille, France; 12AP-HP Hopital Beaujon, Clichy, France; 13AP-HP Hopital Cochin, Paris, France; 14AP-HP Hopital Saint-Antoine, Paris, France; 15CHU de Bordeaux – Hopital Haut-Leveque, Pessac, France; 16CHU de Toulouse – Hopital Purpan, Toulouse, France; 17CHU de Clermont-Ferrand, Clermont-Ferrand, France; 18CHU de Rouen, Rouen, France; 19CHU de Strasbourg – Hopital Hautepierre, Strasbourg, France; 20CHU de Limoges, Limoges, France; 21CHU de Tours – Hopital Trousseau, Tours, France; 22CHU de Montpellier – Hopital Saint-Eloi, Montpellier, France; 23CHU de Grenoble – Hopital Michallon, Grenoble, France; 24HCL – Hopital Edouard Herriot, Lyon, France

Abstract 202
Curing Decompensated Wait Listed HCV Patients with the New DAAs: The Potential Significant Impact on Liver Transplant Wait List and Organ Allocation
Santiago J. Munoz, David J. Reich, Kenneth D. Rothstein, Gary S. Xiao, Vishal Patel, Gwen L. McNulty, Riera Andres, Guy R. Stephen; Liver Transplantation, Hahnemann Univ Hospital Drexel College of Medicine, Cinnaminson, NJ

Pre-treatment NS5A RAVs
Abstract 91
Prevalence of Pre-Treatment NS5A Resistance Associated Variants in Genotype 1 Patients Across Different Regions Using Deep Sequencing and Effect on Treatment Outcome with LDV/SOF
Stefan Zeuzem2, Masashi Mizokami3, Stephen Pianko4, Alessandra Mangia5, Kwang-Hyub Han6, Ross Martin1, Evguenia S. Svarovskaia1, Hadas Dvory-Sobol1, Brian Doehle1, Phillip S. Pang1, Steven J. Knox1, John G. McHutchison1, Diana M. Brainard1, Michael D. Miller1, Hongmei Mo1, Wan-Long Chuang7, Ira M. Jacobson8, Gregory Dore9, Mark S. Sulkowski10; 1Gilead Sciences Inc, Foster City, CA; 2Department of Internal Medicine, J.W. Goethe University Hospital, Frankfurt am Main, Germany; 3National Center for Global Health and Medicine, Tokyo, Japan; 4Department of Gastroenterology, Monash Medical Centre, Victoria, VIC, Australia; 5Liver Unit, IRCCS-Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy; 6Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea (the Republic of); 7Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; 8Medicine, Mt. Sinai Beth Israel, New York, NY; 9Kirby Institute, UNSW Australia, Sydney, NSW, Australia; 10School of Medicine, Johns Hopkins University, Baltimore, MD

Retreatment of DAA failures and evolution of RAVs
Abstract 92
Highly Successful Retreatment with Ledipasvir (LDV) and Sofosbuvir (SOF) in HCV GT-1 Patients Who Failed Initial Short Course Therapy with Combination DAA Regimens (NIH SYNERGY Trial)
Eleanor Wilson1,2, Sarah Kattakuzhy1, Zayani Sims2, Mary McLaughlin3, Angie Price1, Hongmei Mo4, Anu Osinusi4, Henry Masur2, Anita Kohli5, Shyam Kottilil1; 1Infectious Disease, Institute for Human Virology/University of Maryland School of Medicine, Rockville, MD; 2Critical Care Medicine Department, National Institutes of Health, Bethesda, MD; 3National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; 4Gilead Sciences, Foster City, CA; 5Hepatology, St. Joseph’s Hospital and Medical Center, Phoenix, AZ

Abstract 220
Evolution Of Resistance Associated Variants During Initial Treatment, Viral Failure, And Re-Treatment With Directly Acting Antiviral Therapy (NIH SYNERGY Trial)
Sarah Kattakuzhy2,3, Eleanor Wilson2,3, Sreetha Sidharthan3, Mary McLaughlin4, Rachel Silk2, Hongmei Mo5, Anu Osinusi5, Anita Kohli6,1, Henry Masur3, Shyam Kottilil2,3; 1Laboratory of Immunoregulation, NIH, Leidos Biomedical Research Inc., Bethesda, MD; 2Infectious Disease, University of Maryland School
of Medicine, Institute of Human Virology, Baltimore, MD; 3Critical Care Medicine, National Institutes of Health, Bethesda, MD; 4National Institute of Allergy and Infectious Disease, Bethesda, MD; 5Gilead Sciences, Inc., Foster City, CA; 6Hepatology, Creighton University, Phoenix, AZ

Investigational Gilead regimens
 Abstract 38
Sofosbuvir/GS-5816+GS-9857 for 6 or 8 Weeks in Genotype 1 or 3 HCV-infected Patients
Edward J. Gane1, Robert H. Hyland2, Yin Yang2, Luisa M. Stamm2, Diana M. Brainard2, John G. McHutchison2, Catherine A. Stedman3; 1Auckland Clinical Studies, Auckland, New Zealand; 2Gilead Sciences, Inc, Foster City, CA; 3Christchurch Clinical Studies Trust, Christchurch, New Zealand

Abstract 205
A Randomized Controlled Trial of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks Compared to Sofosbuvir with Ribavirin for 12 Weeks in Genotype 2 HCV Infected Patients: The Phase 3 ASTRAL-2 Study
Mark S. Sulkowski1, Norbert Brau2, Eric Lawitz3, Mitchell L. Shiffman4, William J. Towner5, Peter J. Ruane6, Brian Doehle7, Jing Wang7, John McNally7, Anu Osinusi7, Diana M. Brainard7, John G. McHutchison7, Nancy Reau8, Keyur Patel9; 1Johns Hopkins University, Baltimore, MD; 2James J. Peters VA Medical Center, Bronx, NY and Icahn School of Medicine at Mount Sinai, New York, NY; 3Texas Liver Institute, University Of Texas Health Science Center, San Antonio, TX; 4Liver Institute of Virginia, Richmond, VA; 5Kaiser Permanente, Los Angeles, CA; 6Ruane Medical, Los Angeles, CA; 7Gilead Sciences, Inc., Foster City, CA; 8University of Chicago Medical Center, Chicago, IL; 9Duke University School of Medicine, Durham, NC

Abstract 247
High Rates of SVR in Treatment-Experienced Patients with Genotype 1 HCV Infection and Cirrhosis After Treatment with Ledipasvir/Sofosbuvir and Vedroprevir with or Without Ribavirin for 8 weeks
Eric Lawitz1, Fred Poordad1, Robert H. Hyland2, Lin Liu2, Hadas S. Dvory2, Phillip S. Pang2, Diana M. Brainard2, Julio A. Gutierrez1; 1Texas Liver Institute, San Antonio, TX; 2Gilead Sciences, Inc, Foster City, CA

Investigational Abbvie regimens
Abstract 41
98%–100% SVR4 in HCV Genotype 1 Non-Cirrhotic Treatment-Naïve or Pegylated Interferon/Ribavirin Null Responders With the Combination of the Next Generation NS3/4A Protease Inhibitor ABT-493 and NS5A Inhibitor ABT-530 (SURVEYOR-1)
Fred Poordad2, Franco Felizarta3, Armen Asatryan1, Tarek I. Hassanein4, Humberto I. Aguilar5, Jacob P. Lalezari6, J. Scott Overcash7, Teresa Ng1, Ran Liu1, Chih-Wei Lin1, Federico J. Mensa1, Jens Kort1; 1AbbVie, Inc., North Chicago, IL; 2Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX; 3Private practice, Bakersfield, CA; 4Southern California GI and Liver Centers and Southern California Education and Research Center, Coronado, CA; 5Louisiana Research Center, Shreveport, LA; 6Quest Clinical Research, San Francisco, CA; 7eStudySite, San Diego, CA

Abstract 248
High SVR4 Rates Achieved With the Next Generation NS3/4A Protease Inhibitor ABT-493 and NS5A Inhibitor ABT-530 in Non-Cirrhotic Treatment-Naïve and Treatment-Experienced Patients With HCV Genotype 3 Infection (SURVEYOR-2)
Paul Y. Kwo1, Michael Bennett2,3, Stanley Wang4, Hugo E. Vargas5, David L. Wyles6, J. Scott Overcash7, Peter J. Ruane8, Benedict Maliakkal9, Asma Siddique10, Bal R. Bhandari11, Fred Poordad12, Ran Liu4, Chih-Wei Lin4, Teresa Ng4, Federico J. Mensa4, Jens Kort4; 1Division of Gastroenterology, Indiana University Medical Center, Indianapolis, IN; 2San Diego Digestive Disease Consultants, Inc., San Diego, CA; 3Medical Associates Research Group, Inc., San Diego, CA; 4AbbVie Inc., North Chicago, IL; 5Mayo Clinic, Phoenix, AZ; 6University of California San Diego, La Jolla, CA; 7eStudySite, San Diego, CA; 8Ruane Medical & Liver Health Institute, Los Angeles, CA; 9University of Rochester Medical Center, Rochester, NY; 10Virginia Mason Hospital and Medical Center, Seattle, WA; 11Gastroenterology & Nutritional Medical Services, Bastrop, LA; 12Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX

Abstract 250
High SVR4 Rates Achieved With the Next Generation NS3/4A Protease Inhibitor ABT-493 and NS5A Inhibitor ABT-530 in Non-Cirrhotic Treatment-Naïve and Treatment-Experienced Patients With HCV Genotype 2 Infection (SURVEYOR-2)
David L. Wyles2, Mark S. Sulkowski3, Stanley Wang1, Michael Bennett4, Hugo E. Vargas5, J. Scott Overcash6, Benedict Maliakkal7, Asma Siddique8, Bal R. Bhandari9, Fred Poordad10, Sandra S. Lovell1, Chih-Wei Lin1, Teresa Ng1, Federico J. Mensa1, Jens Kort1; 1AbbVie, Inc., North Chicago, IL; 2University of California San Diego, La Jolla, CA; 3Johns Hopkins University School of Medicine, Baltimore, MD; 4San Diego Digestive Disease Consultants, Inc., and Medical Associates Research Group, Inc., San Diego, CA; 5Mayo Clinic, Pheonix, AZ; 6eStudySite, San Diego, CA; 7University of Rochester Medical Center, Rochester, NY; 8Virginia Mason Hospital and Medical Center, Seattle, WA; 9Gastroenterology & Nutritional Medical Services, Bastrop, LA; 10Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX

No Replies to "Key AASLD 2015 HCV Abstracts: Dr. Lebovics"

    Join the discussion

    Some html is OK